The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
复制标题
DOI：
10.1016/s0140-6736(21)00085-4
复制
发表时间：
2021-01-30
期刊：
影响因子：
--
通讯作者：
Cooke E
中科院分区：
文献类型：
--
作者：
Cavaleri M;Enzmann H;Straus S;Cooke E
很少有药物能像COVID-19疫苗那样令人期待。科学家、监管机构和开发人员的非凡努力使欧洲药品管理局（EMA）能够推荐BioNTech COVID-19 mRNA疫苗（核苷修饰）BNT 162 b2（Comirnaty）的首个欧盟有条件上市许可（CMA）
Few medicines are awaited as eagerly as COVID-19 vaccines. Extraordinary efforts by scientists, regulators, and developers enabled the European Medicines Agency (EMA) to recommend the first EU conditional marketing authorisation (CMA) for the BioNTech COVID-19 mRNA vaccine (nucleoside-modified) BNT162b2 (Comirnaty)